U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C27H28N2O7
Molecular Weight 492.5215
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of CILNIDIPINE

SMILES

CC1=C(C(c2cccc(c2)N(=O)=O)C(=C(C)N1)C(=O)OCCOC)C(=O)OC/C(/[H])=C(\[H])/c3ccccc3

InChI

InChIKey=KJEBULYHNRNJTE-DHZHZOJOSA-N
InChI=1S/C27H28N2O7/c1-18-23(26(30)35-14-8-11-20-9-5-4-6-10-20)25(21-12-7-13-22(17-21)29(32)33)24(19(2)28-18)27(31)36-16-15-34-3/h4-13,17,25,28H,14-16H2,1-3H3/b11-8+

HIDE SMILES / InChI

Molecular Formula C27H28N2O7
Molecular Weight 492.5215
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 1
Optical Activity ( + / - )

Description
Curator's Comment:: Description was created based on several sources, including http://www.nevapress.com/cdr/full/17/4/341.pdf | https://www.ncbi.nlm.nih.gov/pubmed/19426250

Cilnidipine (FRC-8653) is a dihydropyridine (DHP) type of calcium channel antagonist. The L-type Ca2+ channel blockade by cilnidipine affects predominantly vascular smooth muscle, thereby producing vasodilation of peripheral resistance vessels and coronary arteries. The blockade of N-type Ca2+ channels affects predominantly peripheral nerve endings of sympathetic neurons, thereby dilating blood vessels by lowering plasma catecholamine levels. Furthermore, renoprotective and neuroprotective effects as well as cardioprotective action of cilnidipine have been demonstrated in clinical practice or animal examinations. Cilnidipine was originated by Fuji & Rebio Pharmaceutical Co., Ltd. and developed jointly with Ajinomoto for the treatment of hypertension. Cilnidipine has been launched in Japan.

CNS Activity

Curator's Comment:: Cilnidipine is brain penetrant and CNS active in animal studies. No human data available.

Approval Year

PubMed

PubMed

TitleDatePubMed
Comparison of 24-hour blood pressure, heart rate, and autonomic nerve activity in hypertensive patients treated with cilnidipine or nifedipine retard.
1998 Aug
Comparison of the direct negative dromotropic effect of a new calcium channel blocker, cilnidipine, with that of nicardipine.
2005 May
Patents

Sample Use Guides

Normally once daily 5 to 10 mg of cilnidipine after breakfast orally for adult patient. The dose can be increased or reduced according to the age and symptoms. If the above dose is not effective enough, the dose can be increased to 20 mg once daily. For severe hypertension, 10 to 20 mg of cilnidipine orally once daily after breakfast.
Route of Administration: Oral
Cell viability of PC12 was not affected by low concentrations of cilnidipine up to 150 uM, but it was slightly decreased at 200 uM cilnidipine.
Substance Class Chemical
Created
by admin
on Sat Jun 26 09:40:59 UTC 2021
Edited
by admin
on Sat Jun 26 09:40:59 UTC 2021
Record UNII
97T5AZ1JIP
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CILNIDIPINE
INN   JAN   MART.   MI   WHO-DD  
INN  
Official Name English
CILNIDIPINE [JAN]
Common Name English
CILNIDIPINE [INN]
Common Name English
SISCARD
Brand Name English
FRC-8653
Code English
CILNIDIPINE [MART.]
Common Name English
ATELEC
Brand Name English
(+/-)-(E)-CINNAMYL 2-METHOXYETHYL 1,4-DIHYDRO-2,6-DIMETHYL-4-(M-NITROPHENYL)-3,5-PYRIDINEDICARBOXYLATE
Systematic Name English
CILNIDIPINE [WHO-DD]
Common Name English
CINALONG
Brand Name English
CILNIDIPINE [MI]
Common Name English
3,5-PYRIDINEDICARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-4-(3-NITROPHENYL)-, 3-(2-METHOXYETHYL) 5-((2E)-3-PHENYL-2-PROPEN-1-YL) ESTER
Systematic Name English
Classification Tree Code System Code
WHO-VATC QC08CA14
Created by admin on Sat Jun 26 09:40:59 UTC 2021 , Edited by admin on Sat Jun 26 09:40:59 UTC 2021
WHO-ATC C08CA14
Created by admin on Sat Jun 26 09:40:59 UTC 2021 , Edited by admin on Sat Jun 26 09:40:59 UTC 2021
Code System Code Type Description
MESH
C065927
Created by admin on Sat Jun 26 09:40:59 UTC 2021 , Edited by admin on Sat Jun 26 09:40:59 UTC 2021
PRIMARY
CAS
132203-70-4
Created by admin on Sat Jun 26 09:40:59 UTC 2021 , Edited by admin on Sat Jun 26 09:40:59 UTC 2021
PRIMARY
CAS
102106-21-8
Created by admin on Sat Jun 26 09:40:59 UTC 2021 , Edited by admin on Sat Jun 26 09:40:59 UTC 2021
NON-SPECIFIC STEREOCHEMISTRY
NCI_THESAURUS
C171754
Created by admin on Sat Jun 26 09:40:59 UTC 2021 , Edited by admin on Sat Jun 26 09:40:59 UTC 2021
PRIMARY
MERCK INDEX
M3548
Created by admin on Sat Jun 26 09:40:59 UTC 2021 , Edited by admin on Sat Jun 26 09:40:59 UTC 2021
PRIMARY Merck Index
PUBCHEM
5282138
Created by admin on Sat Jun 26 09:40:59 UTC 2021 , Edited by admin on Sat Jun 26 09:40:59 UTC 2021
PRIMARY
FDA UNII
97T5AZ1JIP
Created by admin on Sat Jun 26 09:40:59 UTC 2021 , Edited by admin on Sat Jun 26 09:40:59 UTC 2021
PRIMARY
DRUG CENTRAL
642
Created by admin on Sat Jun 26 09:40:59 UTC 2021 , Edited by admin on Sat Jun 26 09:40:59 UTC 2021
PRIMARY
IUPHAR
7767
Created by admin on Sat Jun 26 09:40:59 UTC 2021 , Edited by admin on Sat Jun 26 09:40:59 UTC 2021
PRIMARY
EPA CompTox
132203-70-4
Created by admin on Sat Jun 26 09:40:59 UTC 2021 , Edited by admin on Sat Jun 26 09:40:59 UTC 2021
PRIMARY
ChEMBL
CHEMBL452076
Created by admin on Sat Jun 26 09:40:59 UTC 2021 , Edited by admin on Sat Jun 26 09:40:59 UTC 2021
PRIMARY
EVMPD
SUB06268MIG
Created by admin on Sat Jun 26 09:40:59 UTC 2021 , Edited by admin on Sat Jun 26 09:40:59 UTC 2021
PRIMARY
INN
6880
Created by admin on Sat Jun 26 09:40:59 UTC 2021 , Edited by admin on Sat Jun 26 09:40:59 UTC 2021
PRIMARY
DRUG BANK
DB09232
Created by admin on Sat Jun 26 09:40:59 UTC 2021 , Edited by admin on Sat Jun 26 09:40:59 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
ENANTIOMER -> RACEMATE
ENANTIOMER -> RACEMATE
Related Record Type Details
ACTIVE MOIETY